Using Antibody-Drug Conjugates for Treatment of AML
Alexander E. Perl, MD, discusses the use of antibody-drug conjugates in acute myeloid leukemia. Gemtuzumab ozogamicin has already been approved for this patient population.
Alexander E. Perl, MD, associate professor of medicine at the University of Pennsylvania, discusses the use of antibody-drug conjugates (ADC) in acute myeloid leukemia (AML). Gemtuzumab ozogamicin (Mylotarg) has already been approved for this patient population.
This agent was previously approved for relapsed disease, but withdrawn for single-agent use due to toxicity concerns.
Nonetheless, randomized data supported the use of this ADC in patients with AML. It is important to understand in which patients this treatment is most effective, which Perl notes as patients with relatively favorable chemotherapy-sensitive genotypes.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
